Business Description
Seelos Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US03832V3078
Description
Financial Strength
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.21 | |||||
Equity-to-Asset | -6.19 | |||||
Debt-to-Equity | -0.43 | |||||
Debt-to-EBITDA | -0.39 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -95.03 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 15.3 | |||||
3-Year EPS without NRI Growth Rate | 12.1 | |||||
3-Year FCF Growth Rate | 29.7 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
9-Day RSI | 28.9 | |||||
14-Day RSI | 28.99 | |||||
6-1 Month Momentum % | -49.14 | |||||
12-1 Month Momentum % | -85.73 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.14 | |||||
Quick Ratio | 0.14 | |||||
Cash Ratio | 0.08 | |||||
Days Sales Outstanding | 249.36 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -75.3 | |||||
Shareholder Yield % | -391.55 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -4912.25 | |||||
Net Margin % | -4588.37 | |||||
FCF Margin % | -2947.42 | |||||
ROA % | -265.15 | |||||
ROIC % | -155.81 | |||||
ROC (Joel Greenblatt) % | -84472.6 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 1.28 | |||||
EV-to-EBIT | -0.41 | |||||
EV-to-EBITDA | -0.41 | |||||
EV-to-Revenue | 18.56 | |||||
EV-to-FCF | -0.63 | |||||
Earnings Yield (Greenblatt) % | -243.9 | |||||
FCF Yield % | -635.28 |